Physician profile
Arun Sood
NPI 1043620065
$15,672.98
in general payments reported to CMS, 2019-2025
30 companies · $7,581 in 2025
The $7,581 reported for 2025 was more than what 91% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $793 · 2022: $1,693 · 2023: $3,234 · 2024: $2,372 · 2025: $7,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,531 · Consulting Fee: $5,225 · Travel and Lodging: $1,064 · Education: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,531.27 |
| Consulting Fee | $5,225.00 |
| Travel and Lodging | $1,064.27 |
| Education | $366.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $6,890.81 | 2021-2025 | Opzelura |
| Abbvie INC. | $1,797.30 | 2021-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,155.42 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Sun Pharmaceutical Industries INC. | $708.87 | 2021-2025 | Ilumya, Blu-U, Odomzo |
| Lilly USA, LLC | $670.48 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $650.59 | 2021-2025 | Otezla, Enbrel |
| Genzyme Corporation | $647.86 | 2021-2025 | |
| Galderma Laboratories, L.P. | $440.35 | 2023-2025 | Nemluvio, Aklief |
| E.R. Squibb & Sons, L.L.C. | $382.64 | 2023-2025 | Sotyktu |
| Pfizer INC. | $372.01 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $338.48 | 2022-2025 | Dupixent, Libtayo |
| Ucb, INC. | $311.93 | 2023-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $214.06 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $132.08 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $129.10 | 2023-2025 | Adbry, Anzupgo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $111.99 | 2021-2023 | |
| Almirall LLC | $95.73 | 2022-2025 | Klisyri, Seysara |
| Krystal Biotech INC | $93.03 | 2023-2024 | Vyjuvek |
| Carl Zeiss Meditec USA, INC. | $87.56 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $73.30 | 2023-2024 | Jublia, Duobrii, Siliq |
| Lnhc, INC | $62.36 | 2025 | Zelsuvmi |
| Botanix Sb INC | $56.82 | 2025 | Sofdra |
| Organon LLC | $49.94 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.96 | 2023-2025 | Spevigo |
| Verrica Pharmaceuticals INC. | $41.63 | 2024 | Ycanth |
| Biofrontera INC. | $40.47 | 2022-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Mayne Pharma Commercial LLC | $27.43 | 2023 | |
| Epi Health, LLC | $21.91 | 2022 | |
| Journey Medical Corporation | $12.70 | 2022 | |
| Advanced Oxygen Therapy INC. | $8.17 | 2024 | Topical Oxygen Chamber For Extremities |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.